This clinical trial is focused on studying a type of blood cancer called Acute Myeloid Leukemia (AML). The study is specifically looking at adults who have been newly diagnosed with AML and have certain genetic characteristics that may affect their response to treatment. The trial will compare two different treatment approaches. One group of patients will receive standard intensive chemotherapy, while the other group will receive a treatment called CPX-351, which is a combination of two drugs, cytarabine and daunorubicin, delivered in a special form called liposomal. This form helps the drugs stay in the body longer and may improve their effectiveness.

The purpose of the study is to evaluate how well CPX-351 works compared to the standard chemotherapy in terms of overall survival, which means how long patients live after starting treatment. The study will involve patients receiving their assigned treatment and being monitored over time to see how they respond. Some patients may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments more accurately.

Participants in the study will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for several months, with regular check-ups to monitor the patients’ health and response to the treatment. The goal is to find out if CPX-351 can improve survival rates for patients with AML compared to the standard treatment options currently available.